81532-76-5

Basic information

• Product Name: 2-chloro-5,6,7,8-tetrahydroquinazoline
• Synonyms: 2-chloro-5,6,7,8-tetrahydroquinazoline
• CAS NO: 81532-76-5
• Molecular Formula: C₈H₉ClN₂
• Molecular Weight: 169
• Mol File: 81532-76-5.mol
• Article Data: 8

Chemical Properties

• Melting Point: 34-36 °C
• Boiling Point: 324.0±11.0 °C(Predicted)
• Appearance: /
• Density: 1.252±0.06 g/cm3(Predicted)
• PKA: -0.38±0.20(Predicted)
• CAS DataBase Reference: 2-chloro-5,6,7,8-tetrahydroquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-5,6,7,8-tetrahydroquinazoline(81532-76-5)
• EPA Substance Registry System: 2-chloro-5,6,7,8-tetrahydroquinazoline(81532-76-5)

Safety Data

• Hazardous Substances Data: 81532-76-5(Hazardous Substances Data)

Upstream product

• 81532-77-6 5,6,7,8-tetrahydro-2-(1H)-quinazolinone 
• 1127-85-1 2,4-dichloro-5,6,7,8-tetrahydro-quinazoline 
• 35042-48-9 5,6,7,8-tetrahydroquinazoline-2,4(1H,3H)-dione 
• 1655-07-8 ethyl 2-oxocyclohexane carboxylate 

Downstream Products

• 83939-36-0 2-(4-Benzyl-piperazin-1-yl)-5,6,7,8-tetrahydro-quinazoline; hydrochloride 
• 223589-01-3 1-(5,6,7,8-tetrahydroquinazolin-2-yl)-4-(1-[4-chlorophenyl]methyl)-piperazine oxalate 
• 1030377-42-4 2-{(5R)-5-methyl-4-[2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl}-5,6,7,8-tetrahydroquinazoline 
• 1105664-58-1 2-chloro-6,7-dihydroquinazolin-8(5H)-one 

Relevant articles and documents

PYRIDAZINIUM COMPOUNDS FOR USE IN CONTROLLING UNWANTED PLANT GROWTH

Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as herbicides.

Discovery of the dual orexin receptor antagonist [(7 R)-4-(5-chloro-1,3- benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2 H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia

Despite increased understanding of the biological basis for sleep control in the brain, few novel mechanisms for the treatment of insomnia have been identified in recent years. One notable exception is inhibition of the excitatory neuropeptides orexins A and B by design of orexin receptor antagonists. Herein, we describe how efforts to understand the origin of poor oral pharmacokinetics in a leading HTS-derived diazepane orexin receptor antagonist led to the identification of compound 10 with a 7-methyl substitution on the diazepane core. Though 10 displayed good potency, improved pharmacokinetics, and excellent in vivo efficacy, it formed reactive metabolites in microsomal incubations. A mechanistic hypothesis coupled with an in vitro assay to assess bioactivation led to replacement of the fluoroquinazoline ring of 10 with a chlorobenzoxazole to provide 3 (MK-4305), a potent dual orexin receptor antagonist that is currently being tested in phase III clinical trials for the treatment of primary insomnia.

1-(2-NAPHTHYL) AND 1-(2-AZANAPHTHYL)-4-(1-PHENYLMETHYL)PIPERAZINES BEING DOPAMINE D 4? RECEPTOR SUBTYPE LIGANDS

Disclosed are compounds of formula: (I) or pharmaceutically acceptable addition salts thereof, wherein: X, Y and Z are the same or different and represent optionally substituted carbon or nitrogen; R1 and R2 independently represent organic or inorganic substituents; R3 and R4 are variables independently representing inorganic or organic substituents; A represents C1-C4 alkylene; and R5, R6 and R7 independently represent hydrogen or C1-C6 alkyl, which compounds bind selectively with high affinity to the dopamine D4 receptor subtype and are therefore of use in treatment of various neuropsychological disorders.